Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wolfert

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Chembiochem : a European Journal of Chemical Biology|June 4, 2014
Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonistAbu-Baker M Abdel-Aal, Vani Lakshminarayanan, Pamela Thompson, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 16, 2011
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccineVani Lakshminarayanan, Pamela Thompson, Margreet A Wolfert, et al.
Journal of the American Chemical Society|June 27, 2017
Heparan Sulfate Microarray Reveals That Heparan Sulfate-Protein Binding Exhibits Different Ligand RequirementsChengli Zong, Andre Venot, Xiuru Li, et al.
Chemical Science|June 19, 2018
Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragmentNuria Martínez-Sáez, Nitin T Supekar, Margreet A Wolfert, et al.
Human Gene Therapy|April 3, 1998
Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vectorS L Hart, C V Arancibia-Cárcamo, M A Wolfert, et al.
Plos One|January 21, 2016
MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic MiceVani Lakshminarayanan, Nitin T Supekar, Jie Wei, et al.
Cell Reports|June 13, 2019
N-Glycolylneuraminic Acid as a Receptor for Influenza A VirusesFrederik Broszeit, Netanel Tzarum, Xueyong Zhu, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Chembiochem : a European Journal of Chemical Biology|June 4, 2014
Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonistAbu-Baker M Abdel-Aal, Vani Lakshminarayanan, Pamela Thompson, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 16, 2011
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccineVani Lakshminarayanan, Pamela Thompson, Margreet A Wolfert, et al.
Journal of the American Chemical Society|June 27, 2017
Heparan Sulfate Microarray Reveals That Heparan Sulfate-Protein Binding Exhibits Different Ligand RequirementsChengli Zong, Andre Venot, Xiuru Li, et al.
Chemical Science|June 19, 2018
Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragmentNuria Martínez-Sáez, Nitin T Supekar, Margreet A Wolfert, et al.
Human Gene Therapy|April 3, 1998
Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vectorS L Hart, C V Arancibia-Cárcamo, M A Wolfert, et al.
Plos One|January 21, 2016
MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic MiceVani Lakshminarayanan, Nitin T Supekar, Jie Wei, et al.
Cell Reports|June 13, 2019
N-Glycolylneuraminic Acid as a Receptor for Influenza A VirusesFrederik Broszeit, Netanel Tzarum, Xueyong Zhu, et al.
Pageof 7